Overview
The goal of this randomized, crossover, clinical trial is to link: 1) gastrointestinal motility patterns induced by acute consumption of whole and refined grains, 2) enteric microbial production of bioactive metabolites, and 3) circulating postprandial appearance of metabolites important to cardiometabolic health including glucose, triglycerides, and cholesterol.
Participants will be asked to consume a Smartpill monitoring device that records metrics of gastrointestinal motility in response to whole or refined grains, monitor cardiometabolic metabolties over an 8 hour postprandial window, and provide a fecal sample for microbiome-related analyses.
Eligibility
Inclusion Criteria:
- Healthy men and women
Exclusion Criteria:
Physician-Diagnosed:
- Diabetes Mellitus
- Nutrient-malabsorption disorders
- Intestinal Bowel Syndrome (IBS)
- Intestinal Bowel Disease (IBD)
- Bleeding-related disorders
- Grain allergy
- Psychological Disorders
- Stenosis
- Dysphasia
History of:
- Bariatric Surgery
- Gallbladder removal
- Eating disorders
- Antibiotic administration (within the past three months)
- Hormone therapy
- Currently
- Using statins
- Pregnant, lactating, or postmenopausal
- Taking oral hypoglycemic agents or insulin
- Ingesting prescription fiber
- Using cholesterol and bile acid absorption inhibitors
- Ingesting nutrition supplements, not including a daily multivitamin (i.e. herbs, tinctures, and extracts) •Using recreational drugs or alcohol (within the past week)
- Taking anti-histamines
- Taking proton pump inhibitors
- Taking antacids